Profile data is unavailable for this security.
About the company
Revance Therapeutics, Inc. is a biotechnology company that is focused on aesthetic and therapeutic offerings, including neuromodulator product, DaxibotulinumtoxinA for Injection. The DaxibotulinumtoxinA for Injection combines a proprietary stabilizing peptide excipient with purified botulinum toxin that does not contain human or animal-based components. The Company is also evaluating DaxibotulinumtoxinA for Injection in the full upper face, including glabellar lines, forehead lines, and crow’s feet, as well as in two therapeutic indications cervical dystonia and adult upper limb spasticity. It offers products and services for United States aesthetics practices, including the resilient hyaluronic acid (RHA) Collection of dermal fillers and HintMD fintech platform. The RHA Collection of dermal fillers is a filler for the correction of dynamic facial wrinkles and folds. HintMD fintech platform includes integrated smart payment, subscription, and loyalty digital services.
- Revenue in USD (TTM)47.07m
- Net income in USD-303.40m
- Incorporated1999
- Employees470.00
- LocationRevance Therapeutics Inc1222 Demonbreun Street, Suite 2000NASHVILLE 37203United StatesUSA
- Phone+1 (615) 724-7755
- Fax+1 (302) 674-5266
- Websitehttp://www.revance.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Rubius Therapeutics Inc | 0.00 | -173.90m | 1.88bn | 231.00 | -- | 7.10 | -- | -- | -2.08 | -2.08 | 0.00 | 2.94 | 0.00 | -- | -- | 0.00 | -46.97 | -- | -50.66 | -- | -- | -- | -- | -- | -- | -33.62 | 0.2228 | -- | -- | -- | -2.61 | -- | -- | -- |
| Deciphera Pharmaceuticals Inc | 83.66m | -258.17m | 1.91bn | 350.00 | -- | 4.29 | -- | 22.88 | -4.50 | -4.50 | 1.46 | 7.70 | 0.1364 | 0.3573 | 6.44 | 239,040.00 | -42.09 | -41.47 | -46.54 | -45.57 | 97.95 | -- | -308.58 | -946.27 | 6.49 | -- | 0.00 | -- | 68.35 | -- | -38.61 | -- | 106.38 | -- |
| Regenxbio Inc | 161.28m | -145.23m | 1.92bn | 306.00 | -- | 3.78 | -- | 11.90 | -3.56 | -3.56 | 4.02 | 11.92 | 0.2508 | -- | 3.70 | 527,045.80 | -22.58 | -12.90 | -25.16 | -13.80 | 73.78 | 86.71 | -90.05 | -57.21 | -- | -38.67 | 0.00 | -- | 338.70 | 82.72 | -17.44 | -- | 119.95 | -- |
| Cassava Sciences Inc | 0.00 | -12.70m | 1.94bn | 11.00 | -- | 7.02 | -- | -- | -0.3658 | -0.3658 | 0.00 | 6.91 | 0.00 | -- | -- | 0.00 | -8.28 | -32.35 | -8.44 | -33.81 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -36.77 | -- | -- | -- |
| Castle Biosciences Inc | 78.09m | -22.55m | 1.95bn | 199.00 | -- | 4.68 | -- | 24.92 | -0.9869 | -0.9869 | 3.44 | 16.53 | 0.2451 | 6.26 | 5.15 | 392,397.00 | -7.08 | -- | -7.64 | -- | 84.80 | -- | -28.88 | -- | 20.88 | -19.33 | 0.00 | -- | 20.79 | -- | -443.83 | -- | -- | -- |
| Jufeel International Group | 19.35m | 6.62m | 1.95bn | 144.00 | -- | -- | 260.34 | 100.76 | 0.2362 | 0.2362 | 0.6904 | 1.17 | 0.4034 | 1.77 | 24.22 | 134,392.90 | 14.07 | -- | 22.24 | -- | 77.98 | -- | 34.87 | -- | 0.114 | -- | 0.0249 | -- | -36.72 | -- | -56.36 | -- | -- | -- |
| Revance Therapeutics Inc | 47.07m | -303.40m | 2.00bn | 470.00 | -- | 10.73 | -- | 42.48 | -4.72 | -4.72 | 0.7299 | 2.59 | 0.0774 | 4.93 | 136.44 | 100,151.10 | -49.86 | -50.74 | -54.63 | -56.12 | 69.43 | -- | -644.56 | -3,963.97 | 6.00 | -29.90 | 0.6006 | -- | 3,610.65 | 119.61 | -76.94 | -- | 4.84 | -- |
| Ironwood Pharmaceuticals, Inc. | 413.02m | 508.86m | 2.01bn | 232.00 | 3.96 | 3.93 | 3.93 | 4.87 | 3.12 | 3.12 | 2.55 | 3.14 | 0.5694 | -- | 3.98 | 1,780,276.00 | 70.15 | -6.28 | 78.91 | -7.31 | 99.78 | 95.35 | 123.20 | -9.54 | -- | 6.81 | 0.4634 | -- | -9.08 | 21.10 | 80.13 | -- | -14.57 | -- |
| Xencor Inc | 178.63m | 23.52m | 2.02bn | 202.00 | 94.42 | 3.12 | 67.46 | 11.29 | 0.3661 | 0.3661 | 3.06 | 11.09 | 0.2666 | -- | 14.73 | 884,316.80 | 3.51 | -3.44 | 3.83 | -4.05 | -- | -- | 13.17 | -18.23 | -- | -- | 0.00 | -- | -21.70 | 34.61 | -357.98 | -- | 30.23 | -- |
| Amarin Corporation plc (ADR) | 620.41m | 4.32m | 2.03bn | 1.00k | 490.48 | 3.15 | 306.28 | 3.28 | 0.0105 | 0.0105 | 1.57 | 1.63 | 0.6331 | 0.646 | 4.04 | 620,408.00 | 0.4409 | -14.03 | 0.6616 | -21.66 | 79.32 | 77.19 | 0.6963 | -19.18 | 1.95 | -- | 0.00 | -- | 42.89 | 49.67 | 20.51 | -- | 55.18 | -- |
| Harmony Biosciences Holdings Inc | 235.39m | 17.19m | 2.10bn | 150.00 | 126.54 | 16.57 | 63.65 | 8.91 | 0.2907 | 0.2907 | 4.07 | 2.22 | 0.8908 | 11.63 | 10.14 | 1,569,280.00 | 8.78 | -- | 9.86 | -- | 82.62 | -- | 9.86 | -- | 5.46 | 1.91 | 0.6072 | -- | 2,564.59 | -- | 65.89 | -- | -- | -- |
| Myovant Sciences Ltd | 67.05m | -283.93m | 2.10bn | 407.00 | -- | -- | -- | 31.35 | -3.13 | -3.13 | 0.7399 | -4.35 | 0.1569 | -- | -- | 164,734.60 | -66.46 | -110.31 | -114.88 | -176.33 | 85.63 | -- | -423.49 | -1,758.89 | 2.27 | -24.64 | -- | -- | -- | -- | 11.71 | -- | -- | -- |
| Organogenesis Holdings Inc | 433.35m | 70.06m | 2.14bn | 910.00 | 29.60 | 11.94 | 27.23 | 4.94 | 0.5628 | 0.5628 | 3.42 | 1.39 | 1.52 | 3.67 | 7.18 | 476,213.20 | 24.49 | -7.75 | 33.25 | -9.04 | 76.02 | -- | 16.17 | -11.31 | 2.05 | 7.70 | 0.3181 | -- | 29.63 | -- | 143.67 | -- | -- | -- |
| Atea Pharmaceuticals Inc | 175.01m | 35.29m | 2.17bn | 49.00 | 66.49 | 3.63 | 61.49 | 12.41 | 0.3945 | 0.3945 | 2.06 | 7.22 | 0.3531 | -- | -- | 4,487,411.00 | 7.12 | -- | 9.93 | -- | -- | -- | 20.16 | -- | -- | -- | 0.00 | -- | -- | -- | 22.00 | -- | -- | -- |
| Rocket Pharmaceuticals Inc | 0.00 | -164.70m | 2.18bn | 91.00 | -- | 4.43 | -- | -- | -2.81 | -2.81 | 0.00 | 7.71 | 0.00 | -- | -- | 0.00 | -37.09 | -28.32 | -39.12 | -30.01 | -- | -- | -- | -- | -- | -46.74 | 0.0501 | -- | -- | -- | -80.79 | -- | 134.25 | -- |
| ADC Therapeutics SA | 3.76m | -200.35m | 2.21bn | 208.00 | -- | 9.08 | -- | 588.88 | -2.61 | -2.61 | 0.049 | 3.18 | 0.009 | -- | -- | 18,076.92 | -47.80 | -- | -53.05 | -- | 96.78 | -- | -5,328.54 | -- | 7.51 | -- | 0.2896 | -- | -100.00 | -- | -111.44 | -- | -- | -- |
Data as of Sep 20 2021. Currency figures normalised to Revance Therapeutics Inc's reporting currency: US Dollar USD
45.83%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 30 Jun 2021 | 4.69m | 6.52% |
| GIC Pte Ltd. (Investment Management)as of 31 Dec 2020 | 3.83m | 5.33% |
| The Vanguard Group, Inc.as of 30 Jun 2021 | 3.42m | 4.76% |
| JPMorgan Investment Management, Inc.as of 30 Jun 2021 | 3.38m | 4.71% |
| Palo Alto Investors LPas of 30 Jun 2021 | 3.20m | 4.46% |
| AllianceBernstein LPas of 30 Jun 2021 | 3.09m | 4.30% |
| Capital Research & Management Co. (World Investors)as of 30 Jun 2021 | 2.97m | 4.13% |
| ArrowMark Colorado Holdings LLCas of 30 Jun 2021 | 2.88m | 4.01% |
| Wellington Management Co. LLPas of 30 Jun 2021 | 2.77m | 3.86% |
| Fidelity Management & Research Co. LLCas of 30 Jun 2021 | 2.70m | 3.75% |
More ▼
Data from 30 Jun 2021 - 14 Sep 2021Source: FactSet Research Systems Inc.
